Tamoxican 20 (Tamoxifen/Nolvadex 20mg)

Description

Tamoxican delivers 20mg of Tamoxifen Citrate — the SERM that has protected more physique athletes from gynecomastia and driven more successful post-cycle recoveries than any other compound in the history of performance pharmacology. As a selective oestrogen receptor modulator, Tamoxifen acts as an oestrogen antagonist in breast tissue (blocking receptor-mediated growth signalling) while acting as an agonist in bone and the liver — a tissue-selective profile that makes it uniquely suited to gynecomastia prevention and treatment. At the pituitary, Tamoxifen’s anti-oestrogenic effects disinhibit LH and FSH secretion, stimulating endogenous testosterone production during PCT. At 20mg, this is the standard therapeutic dose: deployed at 20–40mg daily for active gyno management, 20mg daily during PCT, and 10–20mg during aromatising cycles as preventative cover. Tamoxifen also preserves HDL cholesterol better than AIs, making it a cardiovascular-friendlier oestrogen management tool. Verified at 99%+ purity by Puralytix. For PCT: 40mg daily for weeks 1–2, 20mg daily for weeks 3–4, with the option to extend to 6 weeks on heavily suppressive cycles. For gynecomastia treatment: 20–40mg daily for 6–12 weeks can produce regression of early-stage gyno tissue. Tamoxifen also preserves bone mineral density and has a favourable lipid profile versus the AI alternatives — a comprehensive SERM with decades of safety data.